Meeting
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
Authors
Robert L. Ferris
University of Pittsburgh Medical Center Cancer Center Pavilion, Pittsburgh, PA
Robert L. Ferris , Lisa Licitra , Jérôme Fayette , Caroline Even , George R. Blumenschein Jr., Kevin Harrington , Joel Guigay , Everett E. Vokes , Nabil F. Saba , Robert I. Haddad , Shanmugasundaram Ramkumar , Jeffrey Russell , Peter Brossart , Makoto Tahara , Manish Monga , Jin Zhu , A. Dimitrios Colevas , Maura L. Gillison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02105636
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6020)
DOI
10.1200/JCO.2017.35.15_suppl.6020
Abstract #
6020
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
First Author: Nabil F. Saba
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
First Author: Maura L. Gillison
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2022 ASCO Annual Meeting
Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
First Author: Ye Guo